Furthermore, the analysis points to the upcoming ExcelsiusFlex (EFlex) stock as an additional growth driver for Globus Medical (NYSE:GMED) in the orthopedic robotics space. With an estimated 1.1 million total knee arthroplasty (TKA) procedures expected in the US during 2024, and with around 20% projected to use robotic assistance, the opportunity for revenue growth is significant.
The firm estimates that each 1% share gain in the procedure market could translate to over $11 million in revenue. This growth potential is supported by InvestingPro data, which reveals 8 analysts have revised their earnings upward for the upcoming period, with the company expected to maintain profitability this year.
For deeper insights into Globus Medical (TASE:PMCN)'s growth prospects and financial health, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
This growth potential is supported by InvestingPro data, which reveals 8 analysts have revised their earnings upward for the upcoming period, with the company expected to maintain profitability this year.
For deeper insights into Globus Medical's growth prospects and financial health, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
Furthermore, the analysis points to the upcoming ExcelsiusFlex (EFlex) as an additional growth driver for Globus Medical in the orthopedic robotics space.
With an estimated 1.1 million total knee arthroplasty (TKA) procedures expected in the US during 2024, and with around 20% projected to use robotic assistance, the opportunity for revenue growth is significant.
The firm estimates that each 1% share gain in the procedure market could translate to over $11 million in revenue. This growth potential is supported by InvestingPro data, which reveals 8 analysts have revised their earnings upward for the upcoming period, with the company expected to maintain profitability this year.
For deeper insights into Globus Medical's growth prospects and financial health, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
Furthermore, the analysis points to the upcoming ExcelsiusFlex (EFlex) as an additional growth driver for Globus Medical in the orthopedic robotics space. With an estimated 1.1 million total knee arthroplasty (TKA) procedures expected in the US during 2024, and with around 20% projected to use robotic assistance, the opportunity for revenue growth is significant. The firm estimates that each 1% share gain in the procedure market could translate to over $11 million in revenue.
The analyst also provided projections for the placement of the EFlex system, estimating potential sales of $12.5 million to $25 million, depending on the number of systems placed. This is in addition to potential rental agreements that may contribute to revenue.
Overall, the consensus estimates suggest a total year-over-year revenue growth of 16.5% in 2025 for Globus Medical's Enabling Technologies, with the detailed analysis indicating that there could be an upside risk to these numbers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.